Objective: Several interventions promote axonal growth and functional recovery when initiated shortly after central nervous system injury, including blockade of myelin-derived inhibitors with soluble Nogo receptor (NgR1, RTN4R) decoy protein. We examined the efficacy of this intervention in the much more prevalent and refractory condition of chronic spinal cord injury. Methods: We eliminated the NgR1 pathway genetically in mice by conditional gene targeting starting 8 weeks after spinal hemisection injury and monitored locomotion in the open field and by video kinematics over the ensuing 4 months. In a separate pharmacological experiment, intrathecal NgR1 decoy protein administration was initiated 3 months after spinal cord contusion injury. Locomotion and raphespinal axon growth were assessed during 3 months of treatment between 4 and 6 months after contusion injury. Results: Conditional deletion of NgR1 in the chronic state results in gradual improvement of motor function accompanied by increased density of raphespinal axons in the caudal spinal cord. In chronic rat spinal contusion, NgR1 decoy treatment from 4 to 6 months after injury results in 29% (10 of 35) of rats recovering weight-bearing status compared to 0% (0 of 29) of control rats (p < 0.05). Open field Basso, Beattie, and Bresnahan locomotor scores showed a significant improvement in the NgR-treated group relative to the control group (p < 0.005, repeated measures analysis of variance). An increase in raphespinal axon density caudal to the injury is detected in NgR1 decoy-treated animals by immunohistology and by positron emission tomography using a serotonin reuptake ligand. Interpretation: Antagonizing myelin-derived inhibitors signaling with NgR1 decoy augments recovery from chronic spinal cord injury. ANN NEUROL 2011;70:805-821 S pinal cord injury (SCI) causes profound and persistent neurological deficits, many of which result from the interruption of axonal connectivity. A small number of compounds have been identified that when administered within the first few days subsequent to SCI either limit the extent of cell death following injury to lessen the resulting deficit, or promote the regrowth and/or collateral sprouting of axons to restore functional connectivity, or both.
S
pinal cord injury (SCI) causes profound and persistent neurological deficits, many of which result from the interruption of axonal connectivity. A small number of compounds have been identified that when administered within the first few days subsequent to SCI either limit the extent of cell death following injury to lessen the resulting deficit, or promote the regrowth and/or collateral sprouting of axons to restore functional connectivity, or both. 1, 2 The regrowth of axons that bridge the lesion and the collateral sprouting of injured as well as uninjured fibers rostral and caudal to the lesion play critical roles in determining the extent of neurological recovery. 3, 4 Recent studies have emphasized a tight correlation of sprouting with functional recovery even when frank regeneration is absent. [5] [6] [7] [8] Clinical trials are now testing the efficacy of several of these compounds in acute SCI.
strategies cannot benefit pre-existing chronic SCI, and strategies that promote axonal growth have shown efficacy only when administered shortly after injury. Thus, the prevailing model posits that the benefit of promoting axonal extension and collateral sprouting by blocking extrinsic inhibitors or enhancing intrinsic activators is restricted to the acute stage of injury following trauma, when axons are predicted to exhibit the highest potential for anatomical plasticity. 10 However, a recent study demonstrated that extensive regrowth of injured axons across the lesion site can be induced long after injury. 10 This approach required a combination of peripheral nerve injury, viral injection, and cell transplantation. Unfortunately, and perhaps unexpectedly, this regrowth did not result in any functional benefit. Thus, axons in the chronic stage postinjury did regrow, but the extension of severed axons alone is insufficient to restore central nervous system (CNS) function. 10 Alternative cell-based multimodal therapies that include a component for blocking extrinsic inhibitors have also shown some success in specific chronic CNS injury models. 11, 12 However, pharmacological therapy for axonal growth with improved function in chronic SCI remains an unattained goal. Myelin limits axonal growth and neurological recovery after SCI. 2 Among the inhibitory myelin proteins are Nogo-A (Rtn4A), myelin-associated glycoprotein (MAG, Siglec-4), and oligodendrocyte myelin glycoprotein (OMgp). Each exhibits affinity for the Nogo-66 receptor (NgR1, Rtn4R), a protein detectable on axons. 13 The Nogo mutant phenotype has been controversial, and depends on the strain background 14 and the lesion model 15 as well as the specific allele, 7, [15] [16] [17] which is crucial to avoid chronic compensatory effects from other loci (Cafferty and Strittmatter, unpublished observations) . For those models with a detectable Nogo-A phenotype, combined deletion of Nogo-A, MAG, and OMgp allows substantial recovery from spinal cord trauma, greater than deletion of Nogo-A alone and much greater than deletion of MAG and OMgp. 7, 14, 15, 18, 19 For the receptor, constitutive deletion of NgR1 expression allows enhanced recovery after SCI or stroke, and permits sprouting and regenerative growth of raphespinal and rubrospinal axons. 20, 21 Sprouting, but not regeneration, of corticospinal fibers is observed. 15, [20] [21] [22] The Nogo, MAG, and OMgp ligands also bind paired-immunoglobulinlike receptor B (PirB) to inhibit axonal growth in vitro. 23 However, PirB mutant mice do not display improved recovery from CNS injury in any model yet tested. 24, 25 The Nogo/NgR1 pathway has been targeted pharmacologically in acute and subacute CNS injury models by various methods. Anti-Nogo-A antibodies bind 1 myelin-associated inhibitory ligand (Nogo-A) and improve recovery when administered to rodents with spinal hemisection or stroke within 1 week of injury. [26] [27] [28] Similar humanized versions of these antibodies are now completing phase 1 clinical trials. 29 An antagonist peptide, NEP1-40, selectively blocks Nogo-66 binding to NgR1 and promotes recovery from dorsal hemisection of thoracic spinal cord, 30, 31 lateral hemisection of cervical cord, 32 and stroke. 33, 34 One NEP1-40 study observed only slight increase in sprouting and inconsistent behavioral improvements. 35 Greatest benefit is obtained by neutralization of all 3 myelin inhibitors with a soluble truncated NgR1 fusion protein, NgR1(310)ecto-Fc. 36 Infusing this NgR1 decoy protein into the CNS within a week of spinal cord dorsal hemisection, stroke, spinal cord contusion, or dorsal rhizotomy increases axonal growth responses and improves behavioral recovery. 21, [37] [38] [39] Downstream of NgR1, RhoA and ROCKII mediate myelin inhibition of axonal growth, and an RhoA inhibitor, ROCK inhibition, and ROCKII gene deletion all promote functional recovery after acute SCI. [40] [41] [42] [43] [44] Critically, none of these interventions, nor any other pharmacological therapy to promote anatomical repair, has been reported to support neurological improvement when administered in the chronic stage postinjury after endogenous tissue responses have stabilized and the natural history is static. We reasoned that because many axonal tracts and intrinsic spinal circuits remain intact in regions proximal and circumferential to SCI sites and are continually exposed to myelin and myelin debris, blockade of myelin inhibitors long after spinal injury might stimulate axonal growth and recovery. We utilized a drug-regulated conditional deletion of NgR1 and a pharmacological treatment with an NgR-Fc decoy protein, AA-NgR(310)ecto-Fc, to test this hypothesis. Here, we provide evidence that blockade of myelin inhibition allows raphespinal axon growth and enhances recovery in chronic SCI. In addition, we describe a clinically adaptable in vivo imaging method to monitor raphespinal axon growth stimulated by NgR decoy protein following chronic spinal contusion injury. Together, these data support a role for pharmacological interventions targeting myelin-associated inhibitors and their receptors as a treatment for chronic SCI.
Materials and Methods

Gene Targeting and Mouse Strains
The multiple cloning site of pBluescriptII-KS(þ) was replaced with a combination of unique restriction sites to facilitate the sequential construction of the targeting construct. The complete plasmid comprises (in order) a 6.6Kb flanking arm of genomic sequence 5 0 to a loxP site introduced at a Xho-I restriction site proximal to the 5 0 end of exon 2 of NgR1, a pGK-NEO cassette flanked by FRT sequences approximately 500nt 3 0 to the predicted end of the NgR1 mRNA, a second loxP site followed by the 86nt preceding the splice acceptor sequence and the first 12nt of exon 2 fused in-frame with enhanced green fluorescent protein (eGFP), including an SV-40 polyadenylation sequence, a 4Kb flanking arm of genomic sequence, and a negative selection cassette containing herpes simplex virus-thymidine kinase. The plasmid containing the targeting construct was linearized at a unique Sfi-I site and electroporated into embryonic stem (ES) cells. ES cells were selected using G418 and FIAU. Chimeric mice were generated and crossed first onto the C57BL/6J strain and then a C57BL/6J strain expressing the Flp recombinase ubiquitously (Flp deleter strain). Progeny of this cross was screened by polymerase chain reaction to confirm the removal of the pGK-NEO cassette. The estrogen-regulated ubiquitous cre recombinase mouse strain pActin-ER-Cre (B6.Cg-Tg[CAG-cre/Esr1]5Amc/J) 45 was obtained from Jackson Laboratories (Bar Harbor, ME). The constitutive mouse strain pActin-Cre (Tg[CAG-cre]1Nagy) was provided by the Yale Animal Genomics Services Center. Tamoxifen was solubilized in corn oil to 10mg/ml by heating to 37 C and sonicating repeatedly. The drug was administered at a dose of 100mg/kg by intraperitoneal injection for 3 consecutive days. Mice were backcrossed to C57Bl6J for >6 generations.
Southern Blot
Genomic DNA was prepared from cerebral cortex and hippocampus. Genomic DNA was digested with Hind-III, separated by electrophoresis, and blotted onto nylon membranes (Brightstar-Plus; Ambion, Austin, TX). The NgR1 probe was amplified with the following primers: NR1 forward, 5 0 -TTC AGA TGT GTG GTT TTG GTG ACC-3 0 (beginning at nt 221 5 0 to the beginning of exon 2), and NR1 reverse: 5 0 -GAA GGT GAG GAG GAA GAG AGG GAG-3 0 (ending at nt 721 5 0 to the beginning of exon 2). The GFP probe corresponded to 400nt of eGFP amplified with GFP forward 5 0 -GGC GAG GGC GAT GCC ACC TAC GGC-3 0 (beginning at nt 100 after the start ATG), and GFP reverse 5 0 -GCG GAT CTT GAA GTT CAC CTT GAT GCC-3 0 (ending at nt 507 after the start ATG). The purified probe template was biotinylated with the BrightStar Psoralen-Biotin Kit (Ambion). Blots were hybridized overnight with denatured probe at 68 C. After washing, bound probe was detected with the BrightStar Biodetect Kit and autoradiography film.
Northern Blot
Cerebral cortex and hippocampus from 1 hemisphere were homogenized in 20 volumes (wt/vol) of Trizol Reagent (Invitrogen, Carlsbad, CA), aliquoted, frozen in liquid nitrogen, and stored at À80 C. Thirty micrograms of total RNA was isolated and then separated on a 1% formaldehyde-agarose gel and blotted to nylon membrane (Brightstar-Plus, Ambion). Probes were prepared with the BrightStar psoralen-biotin nonisotopic labeling kit (Ambion) as described for Southern blotting (above).
The NgR1 probe was prepared by first amplifying the cDNA sequence corresponding to the $600nt carboxyl-terminal half of NgR1 with the following primers: NR1 forward, 5 0 -CAG TAC CTG CGA CTC AAT GAC AAC CCC-3 0 (beginning at nt 757 relative to the start ATG), and NR1 reverse: 5 0 -CTT   CCG GGA ACA ACC TGG CCT CC-3  0 (ending at nt 1,266 relative to the start ATG). The GFP probe is identical to the probe used for Southern blotting. After hybridization, bound probe was detected with the BrightStar Biodetect Kit.
Immunoblots
Cerebral cortex and hippocampus were homogenized in 20 volumes (wt/vol) of 100mM NaCl, 10mM Tris-Cl pH 7.4, and Triton X-100 and sodium dodecyl sulfate were added to 1% and 0.5%, respectively. After centrifugation at 20,000 Â g for 15 minutes, the supernatant was collected and assessed by immunoblot with antibodies directed against either NgR1 (goat antimouse NgR1; R&D Systems, Minneapolis, MN) or GFP (rabbit anti-GFP; Sigma, St Louis, MO). Immunoreactivity was detected with horseradish peroxidase-coupled secondary antibodies (Jackson ImmunoResearch, West Grove, PA) and chemiluminescence (Pierce, Rockford, IL).
Optic Nerve Crush Injury and Regeneration
Cohorts of mice were administered tamoxifen 7 to 9 days prior to injury, as described above. To crush the optic nerve, mice at 8 to 10 weeks of age were anesthetized with an intraperitoneal injection of ketamine (100mg/kg) and xylazine (10mg/kg) and placed in a stereotactic apparatus. Topical 2% lidocaine anesthetic was applied to the eyeball. The right optic nerve was exposed intraorbitally with care taken to avoid damage to the ophthalmic artery. The nerve was injured by crushing with a jeweler's forceps (Dumont #5; Fine Science Tools, Foster City, CA) for 10 seconds at a location 1mm posterior to the eyeball. Two weeks thereafter, animals were anesthetized with an overdose of anesthetic and perfused transcardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde. The optic nerves and retinas were dissected and postfixed in 4% paraformaldehyde for 48 hours. The specimens were then transferred to 30% sucrose for cryoprotection, embedded in optimal cutting temperature medium, and cryosectioned in the longitudinal plane at 16lm thickness. The sections were stained with anti-GAP-43 antibody (1:1,000) followed by a fluorescent-tagged donkey antisheep (immunoglobulin G [IgG]) secondary antibody. Four longitudinal sections of optic nerve were selected from each animal. The number of GAP-43-positive axons was counted at 0.5mm and 1mm distal to the lesion site. The total number of regenerating axons was calculated from these counts. 46 The retina was also examined for ganglion cell survival using anti-bIII tubulin antibody. No differences were detected between different nerve crush groups (data not shown).
Chronic Thoracic Dorsal Hemisection Injury
Dorsal hemisections were performed on mice by a surgeon blind to the cre transgene genotype using methods and postoperative care as described previously. 7, 18 All mice had Basso
Mouse Scale (BMS) scores of 4 at 75 days postinjury prior to tamoxifen treatment by the method described above.
Chronic Rat Spinal Contusion Injury with Prolonged Intracerebroventricular Therapy
Female Sprague-Dawley rats (250-270g, 11-12 weeks of age, n ¼ 70) were anesthetized with intraperitoneal injection of ketamine (60mg/kg) and xylazine (10mg/kg). A laminectomy was conducted at the caudal portion of T6 and all of T7 spinal levels. A T7 moderate contusion injury (10g, 25mm) was produced with the MASCIS impactor. 37, 47, 48 After the contusion, locomotor performance was assessed at 1-week intervals using the Basso, Beattie, and Bresnahan (BBB) score in the open field. Locomotor performance stabilized at a score of 8 by 7 weeks after injury. An intracerebroventricular cannula was used for AANgR(310)ecto-Fc therapy. To avoid any confounding unfavorable effect of the cannula implantation procedure on locomotor scores, a cannula (Alzet Brain Infusion Kit II; ALZA Corporation, Mountain View, CA) was implanted into the right lateral ventricle at 10 weeks after contusion injury as described previously. 21, 49 Briefly, the scalp was opened, a burr hole was drilled through the skull, and a cannula was introduced into the right lateral ventricle at stereotaxic coordinates 0.6mm posterior and 1.2mm lateral to bregma and 4.0mm deep relative to the pial surface. The cannula was connected to an osmotic minipump containing PBS placed subcutaneously over the scapulae. The cannula was fixed in place with cyanoacrylate, and the skin was sutured. Two weeks after cannula implantation (12 weeks after contusion injury), the rats were reanesthetized, and the minipumps were replaced with new osmotic minipumps (ALZA Corporation) connected to the same cannula. These pumps delivered 2.5ll/h for 28 days and were filled with 2.25mg AANgR(310)ecto-Fc (0.29 mg/kg/day) or 2.25mg IgG from rat serum (#14131, 50mg, Sigma) in 2ml PBS. A total of 64 rats survived from contusion injury to 12 weeks and were entered with into the treatment randomization. Rats were randomly assigned to 1 of the 2 groups, and the surgeon was unaware of the assignment. The duration of treatment was 12 weeks. A new osmotic minipump filled with the same amount of AANgR(310)ecto-Fc or rat IgG was switched every 4 weeks.
AA-NgR(310)ecto-Fc Protein
Purified rat protein was produced in Chinese hamster ovary cells and purified as described previously 38 with 1 modification.
Because the wild fusion protein exhibits a high percentage of disulfide bond heterogeneity, a variant was produced in which the 2 Cys residues at position 266 and 309 of the full-length NgR1 were changed to Ala. This AA variant is homogenous with respect to disulfide bonding and is fully active in vitro. 50 
Behavioral Testing
For mouse behavioral observation, the BMS locomotor scale was used. 51 For rat behavioral testing, the BBB locomotor scale was used. 47, 52 All behavioral tests were performed by 2 researchers unaware of the genotype of the mice or of the identity of the compound in the minipump. Observations were made once per week. Grip strength was measured using a Columbus Instruments (Columbus, OH) force meter for a random subset of animals. Each rat was tested 3Â for each limb, and the data were averaged.
Limb Kinematics
One week before initiation of treatment (tamoxifen or AANgR[310]ecto-Fc protein), and several months later near the end of treatment, mice or rats were video-recorded while locomoting to the end of a 1m Plexiglas track. Prior to video monitoring, reflective markers (B&L Engineering, Santa Ana, CA) were attached using nontoxic glue bilaterally to the iliac crest, the head of the humerus, the greater trochanter of the knee, the lateral malleolus, the fifth metatarsal, and the third toe. Recordings were made from 4 synchronized cameras at 100Hz (Basler Vision Technologies, Ahrensburg, Germany) placed at approximately 45 and 135 relative to the position of the track. We utilized the SIMI motion-capture software (SIMI Reality Motion Systems, Unterschleissheim, Germany) to obtain 3-dimensional coordinates of the markers during locomotion. We modeled the hind limb as an interconnected chain of rigid segments. We then extrapolated multiple gait parameters from recordings containing at least 3 consecutive step cycles. Data was exported using the SIMI motion-capture software numerically in Excel (Microsoft Corporation, Redmond, WA) spreadsheets and as individual frame-by-frame images of gait cycles of each animal. We analyzed the position of the toe relative to distance traveled in the y (anterior-posterior) plane and z plane (superior-inferior), after normalizing the position of the toe relative to a fixed iliac crest (rat) or hip (mouse) to analyze the swing phase of the gait cycle. Additional measures were the angle of the ankle joint and the absolute velocity of the foot as functions of time. The gait cycle was defined as a single attempted forward excursion by the hindlimb, as many of the animals were unable to step due to the nature of the injury. Frame-by-frame images were analyzed using ImageJ (National Institutes of Health, Bethesda, MD) and Illustrator (Adobe Systems, San Jose, CA).
Histology and Analysis
Animals were perfused transcardially with PBS, followed by a 4% paraformaldehyde/PBS solution. The spinal cord 10mm rostral to and 10mm caudal to the lesion center was embedded in a glutaraldehyde-polymerized albumin matrix and cut parasagittally in the thickness of 40lm on a vibratome. Transverse sections (40lm) were collected from the spinal cord 11 to 16mm rostral to and 11 to 16mm caudal to the lesion center. 15, 18, 20, 30, 31, 37, 38, 53, 54 Sagittal sections of thoracic spinal cord were incubated with anti-5-hydroxytryptamine (anti-5HT) antibody (1:10,000; Immunostar, Hudson, WI) and then with Alexa Fluor 568-labeled secondary antibody (Invitrogen) to detect raphespinal fibers. 15, 18, 20, 30, 31, 37, 38, 53, 54 Transverse sections 11 to 16mm
caudal to the lesion center were incubated with anti-5HT
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antibody or anti-serotonin transporter antibody (1:10,000 or 1:1,000; Immunostar) and were visualized with appropriate secondary antibody conjugated to Alexa Fluor 568 (Invitrogen).
Image analysis was performed with the National Institutes of Health's ImageJ version 1.62, as described previously. 15, 18, 20, 30, 31, 37, 38, 53, 54 For analysis of serotonin innervation, immunoreactive serotonin fibers in the ventral horn of transverse sections caudal to the lesion center were selected by thresholding; then the length of serotonin fiber per area was measured after using the skeletonize function. For camera lucida tracing of 5HT-immunoreactive fibers, 10 serial sections at 200lm intervals from each animal were photographed digitally, and fibers were traced on a computer using Adobe Photoshop 7.0 software (Adobe Systems, Mountain View, CA).
Positron Image Tomography with [ 11 C]AFM
Cohorts of injured rats were imaged twice, once at 12 weeks after spinal contusion prior to treatment, and again after 12 weeks of treatment. Uninjured control rats or complete transection rats were imaged once. Rats were anesthetized by isoflurane inhalation, and then 50 6 30MBq of [
was administered in sterile saline by tail vein injection (injected mass: 0.12 6 0.09lg). After injection, dynamic positron emission tomography (PET) images were acquired on a high-resolution research tomograph scanner for 2 hours, as described. 55, 56 Images were collected from 3 rats simultaneously in each imaging session, and radioactivity concentration was assessed in the spinal cord at the cervical and lumbar enlargements. A subset of rats was imaged twice with [ 
Results
Conditional Gene Targeting of the ngr1 Locus
To test definitively whether loss of NgR1 function in the chronically injured state might yield functional benefit, we generated a conditionally targeted NgR1 allele, ngr1 flox , by flanking the second exon (containing the entire coding sequence for the mature protein) with loxP sites (Supplementary Fig S1) . In mice harboring a transgene of cre recombinase (Cre) driven by the constitutive b-actin promoter, recombination of the NgR1 allele is essentially complete. To provide temporal control over deletion, we utilized a transgene with this promoter that drives expression of a fusion protein of Cre and a mutant version of the estrogen receptor (ER). 45 Tamoxifen treatment leads to highly efficient NgR1 gene rearrangement and near total loss of mRNA and protein in the adult CNS within 1 week (Fig 1A) . Prior to recombination, this allele expresses NgR1 protein at wild-type (WT) levels (see Fig 1A) . After Cre-mediated recombination, this allele produces detectable GFP mRNA and protein. GFP expression levels are not sufficient to permit visualization of intrinsic GFP fluorescence but can be detected with signal amplification.
To assess the functional completeness of NgR1 loss following tamoxifen treatment, we employed an optic nerve regeneration model. Previous studies have demonstrated that expression of a dominant negative form of NgR1 in retinal ganglion cells with a recombinant virus yields a subtle axon regeneration phenotype that substantially synergizes with an enhancement of intrinsic growth potential by intraocular inflammation. 46 A constitutive null allele of ngr1 has a stronger axonal regeneration phenotype after optic nerve crush that is clearly detectable without zymosan injection or lens injury (see Fig 1B-D) . We examined whether the conditional deletion of ngr1 would produce an axonal regeneration phenotype similar to the constitutive knockout. Axonal regeneration in ngr1 flox/À mice carrying the Cre transgene and treated with tamoxifen 1 week prior to optic nerve crush resembles that in ngr1 À/À mice and is significantly (p < 0.01, analysis of variance [ANOVA]) greater than in WT mice. Axonal regeneration is not as complete in the conditional allele as the constitutive deletion; this is likely to reflect the 7-day pretreatment providing subtotal gene rearrangement (see Fig 1A) . For ngr1 flox/À mice without Cre/ tamoxifen, axonal regeneration was not significantly different from the low WT levels (see Fig 1B, D) . Thus, the conditional allele allows functional deletion of NgR1 in vivo by tamoxifen, and resembles the ngr1 null axonal regeneration phenotype.
Functional Improvement and Raphespinal Growth after Genetic Deletion of NgR1 in Chronic Mouse SCI Next, we utilized the conditional ngr1 allele to assess recovery and axonal growth in the chronic postinjury state. Optic nerve regeneration is not a chronic injury model, as the vast majority of retinal ganglion cells die within 1 month of injury. 57, 58 Instead, we subjected ngr1 flox/À and ngr1 flox/flox mice, of which 18 of 41 also carried the Cre/ Esr1 transgene, to a spinal cord dorsal hemisection injury. Animals were then observed without intervention for 75 days, a duration greater than the time course of natural (limited) recovery (Fig 2A) . At 75 days, prior to tamoxifen treatment when NgR1 expression is at WT levels, no differences in locomotor performance are detected between these genotypes (BMS ¼ 2.95 6 0.15 at 2 months in Fig 2B) . All mice were treated with tamoxifen at 75 days postinjury. elimination was gradual over months, consistent with a chronic anatomical growth response as opposed to an acute biochemical event, which would have been evident within a week as NgR1 protein levels diminished.
Stepping performance was also assessed with highspeed video limb kinematics (Fig 3) . Markers over each joint of both hindlimbs were tracked during unassisted locomotion to provide the most functionally relevant performance. Uninjured mice exhibit robust step cycles, whereas 10 days after a total thoracic transection there is nearly complete paralysis. In mice with intact NgR1 expression, unassisted gait remained significantly impaired 6 to 7 months after dorsal hemisection, as expected for chronic postinjury mice. We focused on measures of the length and height of foot swing with each step cycle for chronic dorsal hemisection mice both before and after tamoxifen administration. Prior to tamoxifen treatment, the Cre-negative and Cre-positive groups displayed similar deficits. The anterior-posterior length of the foot swing relative to the hip was reduced by half compared to uninjured control mice. The vertical height of the foot cycle relative to the hip was also reduced by 50%. After tamoxifen treatment, these limb kinematic measurements in the Cre-negative group at 6 to 7 months were comparable to pretamoxifen 75-day postinjury values, revealing a stable gait impairment, with no change in the length or height of foot swing relative to the hip. In contrast, the average height and length of foot excursions in Cre-positive mice increased during the 5 months after tamoxifen treatment. These values represent statistically significant improvements (p < 0.01, 1-way ANOVA) relative to both the pretamoxifen values and to the Cre-negative group in which NgR1 expression was intact, but are significantly lower than the values for uninjured mice. Thus, foot movements remained restricted compared to uninjured mice, but improved after NgR1 deletion in chronically injured mice. The reproducibility of this phenotype is illustrated for 8 Cre-negative control and 8 Cre-positive mice (Supplementary Fig S2) . Other measures of the gait cycle, including the foot velocity and the ankle angle, are different in the Cre-positive mice (Supplementary Fig S3) . In particular, the ankle angle is more extended in the mice with NgR1 deletion (Cre-positive), and recovers after each step more quickly, than in the mice with NgR1 intact (Cre-negative).
Previously, we observed that following a dorsal hemisection SCI in mice with a constitutive deletion of NgR1, the density of fibers from the descending raphespinal serotonergic system increases caudal to the lesion. 20 In this study, at the conclusion of this extended observation period, we examined the distribution of serotonergic fibers in the spinal cords from both Cre-negative and Cre-positive mice. In both groups, raphespinal fibers were substantially depleted in the ventral horn of the lumbar caudal spinal cord relative to the cervical enlargement (Fig 4) . Mice carrying the Cre transgene and thus lacking NgR1 beginning $75 days after hemisection exhibit increased 5HT fiber density in the lumbar cord relative to Cre-negative controls (see Fig 4B, C) . This increase may reflect axonal growth of spared fibers, longdistance growth of cut fibers, or both. Therefore, axonal growth in 1 or several tracts may contribute to the slow improvement in motor function observed in Cre-positive mice. There was a strong correlation of 5HT axon density with the parameters measured kinematically (see Fig  4D, E) .
Improved Locomotion and Axon Growth after Treatment of Rat Chronic Spinal Contusion with AA-NgR(310)ecto-Fc
Based on these positive results with genetic perturbation of NgR1 expression in chronically injured mice, we next attempted a more clinically relevant pharmacological treatment of chronic spinal cord contusion in rats. A cohort of rats underwent midthoracic contusion; they were not treated for 3 months, but hindlimb locomotor performance was evaluated weekly. The average BBB score at 12 weeks was 7.75 6 0.10, n ¼ 64 (Fig 5A) , meaning that the majority of rats were capable of hindlimb movement, but not weight support. 47, 52 After an intracerebroventricular (i.c.v.) cannula was introduced, rats were randomized to receive either AANgR(310)ecto-Fc or control IgG protein for 12 weeks at a dose of 0.29mg/kg/day 21,37,38 (see Fig 4B) . The initial BBB scores were identical in the 2 groups (see Fig 5) . Twelve weeks later, there was a trend toward improved hindlimb grip strength in rats treated with NgR1 decoy protein (hindlimb force as a percentage of forelimb force, 11.5 6 0.8%, n ¼ 13 in IgG group assessed for grip strength vs 14.5 6 2.2%, n ¼ 12 in NgR group; p ¼ 0.11, 1-tailed t test). However, the more conspicuous behavioral change was the conversion from hindlimb nonweight-bearing to hindlimb weight-bearing locomotion. The number of AA-NgR(310)ecto-Fc-treated animals able to bear weight in the open field increased by 10 (29% of 35 rats, p < 0.05), whereas there was no significant increase in weight bearing in the control IgG group To provide quantitative measurements of open field locomotion, we also monitored limb kinematics in a randomly selected subset of control and AA-NgR(310)ectoFc-treated rats (Fig 6) . In comparison to uninjured animals, the control group at 6 months after contusion injury exhibited multiple deficits. First, whereas the length of the foot swing in the anterior-posterior dimension on each step relative to the iliac crest was maintained at near normal levels, the average foot position was shifted far posterior. This observation is in agreement with a previous study. 59 Second, uninjured rats produced a gait cycle in which the foot was centered under or anterior to the iliac crest, but the chronically contused control rats showed a range of foot position that remained posterior to the iliac crest at all times. In contrast, in the AA-NgR(310)ecto-Fc-treated group, there was significant normalization of foot position. The majority of AANgR(310)ecto-Fc-treated rats moved their foot anterior to the iliac crest with each cycle. The average position of the foot relative to the iliac crest resembled that of uninjured rats to a greater extent than it did the control injury group. The reproducibility of this result is illustrated for 5 IgG protein-treated control and 5 AANgR(310)ecto-Fc-treated rats ( Supplementary Fig S4) . Ankle flexion of the AA-NgR(310)ecto-Fc-treated rats was confined significantly more precisely to the swing phase of the gait cycle than for the IgG-treated rats (Supplementary Fig S5) . For the control IgG group, the ankle angle was extended 200 milliseconds prior to maximal foot movement and remained flexed for 200 milliseconds afterward. In this sense, the NgR-treated rats resembled uninjured rats more closely than did the control injury group. In previous studies examining the potential benefit of NgR1 antagonism following SCI, improved neurological function correlated with axonal growth. 16, 18, 20, 21, [37] [38] [39] Postmortem histological examination of rats treated after acute SCI with NgR(310)ecto-Fc revealed an increase in the density of descending raphespinal axons caudal to the lesion site. 37, 38 Similarly, here we observed increased 5HT fiber length in the lumbar spinal cord after treatment of chronic SCI (Fig 7A-F) . Camera lucida reconstructions of sagittal sections of thoracic spinal cord illustrate increased 5HT-immunoreactive raphespinal fibers throughout the caudal spinal cord of AA-NgR(310)ectoFc-treated rats in comparison to IgG-treated controls (see Fig 7G, H) . As expected, the degree of tissue loss at the injury site was not altered by AA-NgR(310)ecto-Fc treatment at this chronic stage (Supplementary Fig S6) . Whereas there was a trend toward BDA-labeled corticospinal tract (CST) fibers extending into the lesion site, no CST fibers were detected in the spinal cord caudal to the lesion for either group (Supplementary Fig S7) , consistent with findings in subacute treatment of rat contusion injury with NgR(310)ecto-Fc. 37 These data provide histological evidence for axon growth from uninjured and/or injured fibers as a mechanism contributing to the behavioral improvement of rats treated with AANgR(310)ecto-Fc at a chronic stage following spinal contusion.
Positron Emission Tomography Imaging of Raphespinal Growth after NgR1 Decoy Treatment of Chronic Rat Spinal Contusion
Proof of concept clinical trials for chronic SCI would be greatly enhanced by methods to directly monitor the presence of axonal growth noninvasively. Diffusion tensor imaging by magnetic resonance can detect massive disruptions of highly fascicular spinal cord tracts after injury, but it is extremely doubtful that this method can image the branched, tortuous, and disorganized growth of descending raphespinal fibers that occurs after SCI in response to AA-NgR(310)ecto-Fc treatment. 14, 16, 18, 20, 21, 37, 38, 60 To visualize raphespinal axon growth in the caudal spinal cord in vivo, we evaluated imaging of presynaptic serotonin reuptake sites by PET. One ligand, [
11 C]AFM, shows highly selective binding to serotonin transporters (SERT, 5HTT) in vivo. 55, 56 To verify the feasibility of such a PET ligand for use in detecting changes after spinal contusion, we first examined 5HTT immunoreactivity in sagittal sections from injured animals and compared these results to our findings with 5HT immunostaining for raphespinal fibers. We observed an increase in 5HTT fiber length in the caudal spinal cord of NgR(310)ecto-Fc-treated rats that was very similar to the distribution of 5HT-immunolabeled fibers (see Fig  7) . Therefore, we obtained PET images from the spinal cord of anesthetized rats. The 
Discussion
The major finding of the present work is that axon growth and neurological improvement can be achieved with a single molecular intervention in the chronically injured adult CNS. We utilized 2 different interventions in 2 different SCI model systems to verify that NgR1-directed intervention is effective many months after thoracic SCI. In mice, we generated a conditional allele of NgR1 and employed a drug-regulated Cre-dependent deletion strategy to study the role of NgR1 in limiting recovery at a chronic stage following dorsal hemisection SCI. In rats, we utilized intracerebral infusion to evaluate the effects of an NgR1 decoy receptor at a chronic stage after contusion SCI. In both systems, months after thoracic injury, intervention significantly improved open field locomotion, hindlimb kinematics, and caudal raphespinal axon density. These data provide the first demonstration that a directed molecular intervention has preclinical efficacy for improving mammalian neurological function in the chronic stage of CNS damage.
In previous analyses of chronic SCI, cell-based combination therapies have yielded some benefit. Cellular components have included olfactory ensheathing cells, Schwann cells, fibroblasts, neural stem cells, and mesenchymal stem cells. [10] [11] [12] To achieve optimal benefits, cellular transplantation has been combined with a range of interventions, including modifications of cyclic adenosine monophosphate (cAMP) level, surgeries to promote the intrinsic growth stage of the neuron, and neurotrophic factors. None of these interventions has produced significant neurological benefit for chronic SCI in the absence of surgical transplantation. In contrast to chronic SCI, several pharmacological treatments without surgical or cell-based intervention are beneficial in acute or subacute models of SCI. Pharmacological treatments targeting myelin-derived inhibitors, chondroitin sulfate proteoglycans, intracellular RhoA signaling cascades, cAMP levels, and neurotrophic factors are efficacious when employed shortly after injury. 4 Similar to pharmacological intervention, perturbing the expression of single genes to promote axon growth and/or neurological improvement, including PTEN (phosphatase and tensin homolog), 61 Nogo-A, 7, 8, 14, 15, 18 NgR1, 20 and PTP-sigma, 62, 63 has only been effective when performed before or shortly after SCI. The current study establishes the possibility of pharmacological therapy alone as efficacious for chronic CNS injuries such as spinal cord trauma. The locomotor and kinematic improvements observed in chronically injured mice and rats after NgR1 perturbation emerge gradually and correlate with increased serotonin fiber density in the distal spinal cord. Most likely this reflects sprouting of raphespinal fibers. Treatment with the NgR1 decoy protein did not promote long-distance regeneration of corticospinal fibers in the rat chronic contusion model. However, many lines of work support the model that short-range anatomical plasticity such as collateral sprouting can provide substantial functional benefit in the absence of long-distance axon regeneration. For example, the sprouting of uninjured corticospinal fibers after pyramidotomy and after ischemic stroke in constitutive mutant NgR1 mice correlates with functional recovery in the absence of regeneration. 15, 21 This restitution of function may depend in part on the recruitment of intraspinal polysynaptic relays capable of providing substantial neurological replacement for injured long tracts. 5, 64 Thus, an absence of frank corticospinal regeneration does not imply absent restoration of functional polysynaptic circuits. Pharmacological interventions, such as ibuprofen and Y-27632, also promote axonal sprouting and functional recovery after SCI without long distance axonal regeneration. 41, 65 Although the growth of raphespinal serotonin axons in the caudal spinal cord is driven by NgR1 intervention long after SCI, anatomical rearrangements of other injured and uninjured descending and propriospinal fiber tracts at multiple levels of neuraxis are probable contributors to the improvements in locomotion and kinematics observed in this study.
Although sprouting or plasticity are likely to occur with interruption of NgR1 pathways, the optic nerve regeneration studies with constitutive or conditional NgR1 deletion demonstrate that absence of this 1 protein in adult mice permits axonal regeneration per se in vivo. This finding extends previous studies using a dominant negative truncated NgR1 virus in combination with an induction of intrinsic growth potential by macrophage inflammation. 46 Presumably, the more prominent phenotype after genetic deletion reflects incomplete infection with the dominant negative virus coupled with incomplete blockade in the face of continued expression of endogenous NgR1. As NgR1 intervention permits axonal sprouting and functional improvement long after injury, myelin inhibitors may be continuously suppressing CNS rewiring by stabilizing CNS anatomy. This function of myelin-associated inhibitors and NgR1 is consistent with the finding that NgR1 is required to restrict ocular dominance plasticity in the visual system to a developmental critical period. Adult NgR1 mutant mice preserve this experience-dependent plasticity at a level indistinguishable from adolescent critical period mice. 66 Thus, myelin and NgR1 may contribute to consolidating neural circuitry and the efficacy of myelin neutralization to support functional improvement after chronic injury derives from the continuous physiologic role of myelin of dampening anatomical rearrangements at the synaptic level. Acute blockade of NgR1 function within several days of spinal cord contusion improves locomotor recovery, with an average of a 2.75-point improvement on the BBB scale and 2-fold increase in the occurrence of weight-bearing status. 67 The time dependence of benefits from NgR decoy treatment is difficult without direct comparison in the same experiment. However, the benefit for chronic injury appears to be of lesser magnitude than for treatment initiated within a week of contusion. This suggests that NgR1-independent factors allow the recently injured nervous system to more fully capitalize on a growth environment rendered more conducive to growth by NgR1 blockade. The open field BMS and BBB scoring systems have played a key role in the analysis of motor dysfunction after SCI. Limb kinematic analysis is more detailed and provides additional insights into motor performance. 5, 59, 68, 69 Although the use of these systems is increasing, much of the work has been restricted to body weight-supported treadmill stepping. Its use for spontaneous locomotion has been limited. Thus, baseline data for moderately injured mice and rats have few precedents in the literature. The strong correlation between recovery of raphespinal innervation in the lumbar spinal cord and kinematic parameters is consistent with fiber growth mediating return of function.
The type of movement impairment in mice with a chronic dorsal hemisection is distinct from that in rats with a moderate spinal contusion. Chronically injured mice exhibited shortened swing of the foot relative to the hip. In agreement with previous short-term studies, 59 we observed a pronounced effect on limb position in chronically injured rats. The foot was maintained in a posterior position despite relatively preserved anterior-posterior excursions with each gait cycle relative to the iliac crest.
The use of such analysis in a broader range of studies is likely to provide greater insight into the mechanisms and pathways of recovery. In the current study, NgR1 intervention improved limb kinematics to more closely resemble the uninjured state despite treatment being initiated 2 months after injury. Among the parameters derived from kinematic analysis are joint angles. However, the interpretation of such angles in cases of significant dysfunction without assisted stepping is not straightforward. We observed greater ankle angles through the gait cycle in mice with NgR1 deletion. This is consistent with greater strength and weight support, but it might reflect changes in posture or tone rather than strength or coordination. For the spinal contused rats, most animals were not weightsupporting, and full ankle extension/flexion during sweeping gait cycles of the externally rotated hindlimb on the floor were noted. In the NgR-treated rats, ankle angles were linked with greater temporal precision to the gait cycle than in untreated rats. Moreover, the NgRtreated pattern more closely resembled the uninjured ankle angle pattern.
The translation of laboratory findings to clinical studies is strongly facilitated by quantitative biomarkers that monitor the primary mechanism of action. For SCI, functional analysis at the bedside using clinical scores has been the mainstay of analysis. 70 Electrophysiological analysis may provide additional confirmatory measurements, but these have seldom been used clinically or in injury models. To date, magnetic resonance imaging (MRI) studies have been used primarily to define the extent of injury rather than a degree of sprouting, plasticity, repair, or recovery. Although the blood oxygenation level-dependent signal in functional MRI studies and the diffusion tensor method may provide additional insights, they cannot be considered biomarkers for the action of axon growth promoters. 71 Because our anatomical studies demonstrated highly branched sprouting of serotonergic fibers in the lumbar spinal cord, we sought a translatable method to monitor this growth. PET with serotonin transporter ligands provides a method to monitor the action of these interventions that drive neurological recovery and axon growth. Our observation that chronically injured animals can regain neurological function following administration of a single pharmacological reagent has 2 important implications. First, these findings demonstrate that at least 1 axon growth-promoting therapy may have relevance for pre-existing spinal cord trauma. Second, these results may facilitate translational research, because clinical trials of therapies for chronic spinal cord damage can be powered adequately with <10% of the number of patients required for acute therapies. 72 In conclusion, perturbation of NgR1 pathways supports recovery of neurological function in chronic rodent SCI.
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